Characterisation of the first VIM metallo-beta-lactamase-producing Pseudomonas aeruginosa clinical isolate in Serbia

Acta Microbiologica Et Immunologica Hungarica
Zorica LepsanovicMiklós Fuzi

Abstract

From the Central-East European region the first VIM metallo-beta-lactamase (MBL) producing Pseudomonas aeruginosa strains were published from Croatia, Poland and Hungary. The aim of this study was to assess the contribution of MBL-production to carbapenem-resistance among P. aeruginosa clinical isolates in the Military Medical Academy (MMA) in Belgrade, Serbia between August 2004 and September 2007. Only one P. aeruginosa isolate with strain number 722 proved MBL-positive that harboured a novel class 1 integron with a bla(VIM-2)-like cassette in the first position, followed by orfD, a putative gene with unknown function. Our data indicate that MBL-producing strains occur at a prevalence of less than 1% among imipenem-nonsusceptible P. aeruginosa clinical isolates in this Belgrade hospital. The newly identified VIM MBL-producing P. aeruginosa strain 722 could be assigned to serotype O11, and it was panresistant to all antimicrobials tested. The isolate displayed sequence type ST235 by multilocus sequence typing which is the founder sequence type of the previously identified international clonal complex CC11 that already contains bla(VIM)-positive isolates from Italy, Greece, Sweden, Hungary and Poland. In conclusion, this is the...Continue Reading

References

Feb 4, 2003·The Journal of Antimicrobial Chemotherapy·Jean-Denis DocquierGian Maria Rossolini
Sep 16, 2003·Emerging Infectious Diseases·Sanda SardelicGian Maria Rossolini
Apr 28, 2004·Emerging Infectious Diseases·Cristina LagatollaGian Maria Rossolini
May 12, 2004·Diagnostic Microbiology and Infectious Disease·Jing-Jou YanChin-Luan Chuang
Dec 8, 2004·Journal of Clinical Microbiology·Barry CurranChristopher G Dowson
Apr 16, 2005·Clinical Microbiology Reviews·Timothy R WalshPatrice Nordmann
Sep 27, 2006·Antimicrobial Agents and Chemotherapy·Balázs LibischMiklós Füzi
Aug 22, 2007·International Journal of Antimicrobial Agents·Daniela OhlasovaMilan Niks
Feb 15, 2008·The Journal of Antimicrobial Chemotherapy·Elizabeth M Johnson
Mar 28, 2008·Journal of Clinical Microbiology·Balázs LibischMiklós Füzi
Oct 10, 2008·Academic Medicine : Journal of the Association of American Medical Colleges·Rachel YudkowskyMihaela Popescu

❮ Previous
Next ❯

Citations

May 3, 2011·The Lancet Infectious Diseases·Giuseppe CornagliaGian Maria Rossolini
Apr 1, 2011·Future Microbiology·Wei-Hua Zhao, Zhi-Qing Hu
Apr 17, 2015·BMC Infectious Diseases·Mai Mahmoud ZaferSeif El Din Ashour
Dec 5, 2017·Genome Biology and Evolution·Tohru Miyoshi-AkiyamaTeruo Kirikae
Jan 23, 2020·Microbiology and Immunology·Teiji SawaKiyoshi Moriyama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.